![](/img/cover-not-exists.png)
Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells
Zent, Clive S., Taylor, Ronald P., Lindorfer, Margaret A., Beum, Paul V., LaPlant, Betsy, Wu, Wenting, Call, Timothy G., Bowen, Deborah A., Conte, Michael J., Frederick, Lori A., Link, Brian K., BlackVolume:
89
Language:
english
Journal:
American Journal of Hematology
DOI:
10.1002/ajh.23737
Date:
July, 2014
File:
PDF, 625 KB
english, 2014